© 2019 Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología Objective: To assess whether there are any real-life differences between ankylosing spondylitis (AS) patients treated with NSAID or TNF inhibitors (TNFi) regarding disease activity. Methods: This is an observational transversal unicentric study with retrospective retrieval of data from clinical records of all AS patients attended in our hospital. We compared clinical activity measured by Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) scores between patients treated with NSAID and those treated with TNFi, in terms of low disease activity defined as BASDAI< 4, and inactivity when BASDAI ≤ 2. As secondary variables, we also collected epidemiological, clinical and radiological data from all those patients. Results: A total of 152 AS patients (81% male), with an average age of 49.45 ± 12.38 years and a disease duration of 13.5 ± 9.79 years were included in the study. Eighty-nine patients (58.6%) were treated with NSAID and 63 (41.4%) with TNFi. The proportion of patients with low disease activity and inactive disease was significantly higher in the TNFi treatment group compared to the NSAID group (81 vs. 47, P = .0001) and (44 vs. 24, P = .007), respectively. Patients treated with NSAIDs also showed significantly more global pain and night pain than those under TNFi therapy. The BASFI score and especially the type of treatment (NSAID or TNFI) were the only variables independently associated with low disease activity or inactive disease. Conclusion: In real world practice, AS patients under TNFi treatment show a better control of clinical symptoms than those under NSAIDs.
- Ankylosing spondylitis